Every good idea brings a real opportunity

At Grifols, taking on responsibility means showing full commitment to therapeutic advances and the progress of related new scientific knowledge. ALTA is a research initiative funded by Bayer HealthCare Biological Products in 2004 and continued by Talecris Biotherapeutics GmbH. Grifols is now proud to continue the commitment to the Alpha-1 community.

Through ALTA, we promote the realisation of innovative ideas and visions in the field of Alpha-1-Antitrypsin Deficiency (AATD). Our aim is to give novel ideas a real chance. ALTA offers the award winners scientific and financial freedom to pursue clinical and scientific research in AATD and AATD - associated diseases and consequently help to shape the future of AATD therapy.

Grifols funds two research projects each year. With an annual prize fund of EUR 50,000 per fellowship, ALTA is one of the most significant awards in the field of respiratory research.

Achieve more together

Extending the existing network of clinical and academic centres as well as individuals working in the field of AATD is a proclaimed goal of the ALTA program. Grifols is committed to promoting and facilitating collaborations between well-established research groups in the field of AATD.

The ALTA winners are encouraged to conduct all or some of their research project at another national or international centre. The renowned research laboratories headed by the members of the ALTA Review Team would be delighted to host and mentor ALTA fellows for certain aspects of their project.

Motivated clinicians or scientists are invited to enter the competition for an ALTA award and submit their research proposals. The two most promising projects aimed at providing novel insights into the pathophysiology, clinical course, or treatment of AATD and associated conditions will receive an award.

The recipients of the awards will be selected by an independent jury (ALTA Review Team) comprised of seven leading experts in clinical and academic medicine and one representative from Grifols, the Head of Medical Affairs EU and ROW. Each application that meets the terms of entry will be carefully assessed and judged against various criteria. The utmost discretion and confidentiality is assured at all times.